menu
    • menu

    Company profile for Lipocine

    NEW Drugs in Dev: 6
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes TLANDO, LPCN 1144, TLANDO XR ("LPCN 1111"), LPCN 1148 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men....
    Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes TLANDO, LPCN 1144, TLANDO XR ("LPCN 1111"), LPCN 1148 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men. Lipocine received a complete response letter from the FDA related to TLANDO on November 8, 2019.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    LipocineUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    675 Arapeen Drive, Suite 202 Salt Lake City
    Telephone
    Telephone
    801.994.7383
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.lipocine.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lipocine to Host KOL Event on Postpartum Depression and LPCN 1154
    Lipocine to Host KOL Event on Postpartum Depression and LPCN 1154

    04 Jun 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lipocine-inc-to-host-virtual-kol-event-highlighting-unmet-needs-in-postpartum-depression-and-the-clinical-profile-of-lpcn-1154-302790853.html

    PR NEWSWIRE
    04 Jun 2026
    Share Share
    Lipocine LPCN 1154 Phase 3 Data to Be Presented at ASCP 2026
    Lipocine LPCN 1154 Phase 3 Data to Be Presented at ASCP 2026

    19 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lipocine-announces-lpcn-1154-phase-3-data-accepted-for-oral-presentation-at-2026-ascp-annual-meeting-302775087.html

    PR NEWSWIRE
    19 May 2026
    Share Share
    Lipocine to Present at AGP Annual Virtual Healthcare Showcase
    Lipocine to Present at AGP Annual Virtual Healthcare Showcase

    18 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lipocine-to-present-at-agps-annual-virtual-healthcare-company-showcase-302773335.html

    PR NEWSWIRE
    18 May 2026
    Share Share
    Lipocine Reports Q1 2026 Financial Results
    Lipocine Reports Q1 2026 Financial Results

    08 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lipocine-announces-financial-results-for-the-first-quarter-ended-march-31-2026-302766140.html

    PR NEWSWIRE
    08 May 2026
    Share Share
    Lipocine Reports Topline Results for LPCN 1154 in PPD Patients
    Lipocine Reports Topline Results for LPCN 1154 in PPD Patients

    02 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lipocine-reports-topline-safety-and-efficacy-results-for-lpcn-1154-in-patients-with-postpartum-depression-302732160.html

    PR NEWSWIRE
    02 Apr 2026
    Share Share
    Lipocine Reveals Full-Year 2025 Financial Results
    Lipocine Reveals Full-Year 2025 Financial Results

    10 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lipocine-announces-financial-results-for-the-full-year-ended-december-31-2025-302709002.html

    PR NEWSWIRE
    10 Mar 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search